IRIS Accounts Production v24.2.0.383 03234036 Board of Directors 1.1.23 31.12.23 31.12.23 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh032340362022-12-31032340362023-12-31032340362023-01-012023-12-31032340362021-12-31032340362022-01-012022-12-31032340362022-12-3103234036ns15:EnglandWales2023-01-012023-12-3103234036ns14:PoundSterling2023-01-012023-12-3103234036ns10:Director12023-01-012023-12-3103234036ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3103234036ns10:SmallEntities2023-01-012023-12-3103234036ns10:AuditExemptWithAccountantsReport2023-01-012023-12-3103234036ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3103234036ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3103234036ns10:FullAccounts2023-01-012023-12-3103234036ns10:Director22023-01-012023-12-3103234036ns10:RegisteredOffice2023-01-012023-12-3103234036ns5:CurrentFinancialInstruments2023-12-3103234036ns5:CurrentFinancialInstruments2022-12-3103234036ns5:ShareCapital2023-12-3103234036ns5:ShareCapital2022-12-3103234036ns5:RetainedEarningsAccumulatedLosses2023-12-3103234036ns5:RetainedEarningsAccumulatedLosses2022-12-3103234036ns5:PlantMachinery2022-12-3103234036ns5:PlantMachinery2023-01-012023-12-3103234036ns5:PlantMachinery2023-12-3103234036ns5:PlantMachinery2022-12-3103234036ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3103234036ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-31
REGISTERED NUMBER: 03234036 (England and Wales)







Unaudited Financial Statements

for the Year Ended 31 December 2023

for

EDLESBOROUGH PHARMACEUTICAL SUPPLIES
LIMITED

EDLESBOROUGH PHARMACEUTICAL SUPPLIES
LIMITED (REGISTERED NUMBER: 03234036)






Contents of the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4

Chartered Accountants' Report 7

EDLESBOROUGH PHARMACEUTICAL SUPPLIES
LIMITED

Company Information
FOR THE YEAR ENDED 31 DECEMBER 2023







DIRECTORS: Mrs U Patel
M Patel





REGISTERED OFFICE: Edlesborough Pharmacy
11 Cow Lane Edlesborough
Dunstable
Bedfordshire
LU6 2HT





REGISTERED NUMBER: 03234036 (England and Wales)





ACCOUNTANTS: K G Solanki & Co.
Hamilton House
315 St Saviours Road
Leicester
Leicestershire
LE5 4HG

EDLESBOROUGH PHARMACEUTICAL SUPPLIES
LIMITED (REGISTERED NUMBER: 03234036)

Balance Sheet
31 DECEMBER 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 42,653 56,871

CURRENT ASSETS
Stocks 75,922 54,320
Debtors 5 1,987,067 1,545,265
Cash at bank and in hand 377,713 554,069
2,440,702 2,153,654
CREDITORS
Amounts falling due within one year 6 288,974 249,556
NET CURRENT ASSETS 2,151,728 1,904,098
TOTAL ASSETS LESS CURRENT
LIABILITIES

2,194,381

1,960,969

PROVISIONS FOR LIABILITIES 10,805 10,805
NET ASSETS 2,183,576 1,950,164

EDLESBOROUGH PHARMACEUTICAL SUPPLIES
LIMITED (REGISTERED NUMBER: 03234036)

Balance Sheet - continued
31 DECEMBER 2023

2023 2022
Notes £    £    £    £   
CAPITAL AND RESERVES
Called up share capital 110 110
Retained earnings 2,183,466 1,950,054
SHAREHOLDERS' FUNDS 2,183,576 1,950,164

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 21 September 2024 and were signed on its behalf by:





M Patel - Director


EDLESBOROUGH PHARMACEUTICAL SUPPLIES
LIMITED (REGISTERED NUMBER: 03234036)

Notes to the Financial Statements
FOR THE YEAR ENDED 31 DECEMBER 2023

1. STATUTORY INFORMATION

Edlesborough Pharmaceutical Supplies Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


EDLESBOROUGH PHARMACEUTICAL SUPPLIES
LIMITED (REGISTERED NUMBER: 03234036)

Notes to the Financial Statements - continued
FOR THE YEAR ENDED 31 DECEMBER 2023

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 13 (2022 - 10 ) .

4. TANGIBLE FIXED ASSETS
Plant and
machiner
etc
£   
COST
At 1 January 2023
and 31 December 2023 77,477
DEPRECIATION
At 1 January 2023 20,606
Charge for year 14,218
At 31 December 2023 34,824
NET BOOK VALUE
At 31 December 2023 42,653
At 31 December 2022 56,871

EDLESBOROUGH PHARMACEUTICAL SUPPLIES
LIMITED (REGISTERED NUMBER: 03234036)

Notes to the Financial Statements - continued
FOR THE YEAR ENDED 31 DECEMBER 2023

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE
YEAR
2023 2022
£    £   
Trade debtors 139,449 230,459
Amounts owed by group undertakings 1,794,702 1,270,713
Other debtors 52,916 44,093
1,987,067 1,545,265

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE
YEAR
2023 2022
£    £   
Trade creditors 204,082 194,585
Taxation and social security 76,148 53,332
Other creditors 8,744 1,639
288,974 249,556

7. CONTINGENT LIABILITIES

On 17th November 2022 the company assigned fixed and floating charges on the assets of the company in favour of Lloyds Bank plc, as security for debt provided by the Bank to the parent company , Yashnidhi Limited.

8. RELATED PARTY DISCLOSURES

During the year , management fees of £120,000 ( 2022 £120,000) were paid to the parent company Yashnidhi Limited.

9. ULTIMATE CONTROLLING PARTY

On 31st October 2018 the company became a wholly owned subsidiary of Yashnidhi Limited , a company incorporated in England & Wales.

Chartered Accountants' Report to the Board of Directors
on the Unaudited Financial Statements of
Edlesborough Pharmaceutical Supplies
Limited

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Edlesborough Pharmaceutical Supplies Limited for the year ended 31 December 2023 which comprise the Income Statement, Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of Edlesborough Pharmaceutical Supplies Limited, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Edlesborough Pharmaceutical Supplies Limited and state those matters that we have agreed to state to the Board of Directors of Edlesborough Pharmaceutical Supplies Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Edlesborough Pharmaceutical Supplies Limited and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Edlesborough Pharmaceutical Supplies Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Edlesborough Pharmaceutical Supplies Limited. You consider that Edlesborough Pharmaceutical Supplies Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Edlesborough Pharmaceutical Supplies Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






K G Solanki & Co.
Hamilton House
315 St Saviours Road

Chartered Accountants' Report to the Board of Directors
on the Unaudited Financial Statements of
Edlesborough Pharmaceutical Supplies
Limited

Leicester
Leicestershire
LE5 4HG


21 September 2024